Huawei will launch its CE-marked Watch D3 in Portugal on 26 October, combining ambulatory blood-pressure monitoring with a slimmer design and up to six days of battery life.
Huawei is preparing to bring the Watch D3 to Portugal on 26 October, extending its push into medical-grade wearables with a device built around blood-pressure monitoring. The new smartwatch was first unveiled in Munich at the start of September and is being positioned as a tool for people who need regular cardiovascular tracking in day-to-day life, not just occasional readings.
According to Huawei, the Watch D3 is a Class IIa medical device with CE 0197 marking, and it supports ambulatory blood pressure monitoring, or ABPM. That means it can record readings at different points through the day and night, including during sleep, without forcing the wearer to stop what they are doing. The same core approach was used in the earlier Watch D2, which also combined wrist-based measurement with medically oriented reporting.
The company is pitching the watch against a clear public-health backdrop. Data cited by TEK SAPO from the e_COR study suggest that 43.1% of adults in Portugal live with hypertension. The condition often develops without obvious symptoms, while blood pressure naturally changes with stress, exercise and environment, which makes repeated monitoring more informative than a single measurement. A July study carried out by Huawei and Hearst also found that 92% of respondents in Portugal believed tracking blood pressure over time was more useful than a one-off check, although only 20% said they measured it daily.
Huawei is also using the launch to reinforce a wider research strategy. At the European Society of Cardiology congress in Munich, it announced Terve Research, a European platform created with Thryve to support large-scale studies using smartwatch data collected in real-world conditions. The company says the Watch D3 is intended for adults over 18 and should be used alongside medical guidance, with readings interpreted by a doctor rather than used to alter treatment independently.
The hardware has also been redesigned. Huawei says the case is 14% thinner than before, at 11.4mm, while the LTPO AMOLED display has grown to 1.92 inches with a resolution of 480 x 408 pixels and peak brightness of 3,000 nits. Battery life is stated at up to six days in typical use, although that falls to around one day when continuous ambulatory monitoring is active. The pressure-cuff mechanism is still built into the strap and uses an internal micro-pump, but the strap has been narrowed for a less bulky fit. The company will disclose pricing when sales begin in Portugal on 26 October.
Disclaimer: This content is intended for informational purposes only. Readers are advised to exercise their own judgement, conduct due diligence, or consult a qualified expert before acting on any information provided.
